DXCM - デックスコム (DexCom Inc.) デックスコム

 DXCMのチャート


 DXCMの企業情報

symbol DXCM
会社名 DexCom Inc (デックスコム)
分野(sector) Health Care   ヘルスケア
産業(industry) Medical/Dental Instruments  
業種 医療機器_医療用品_ディストリビュ―タ―   医療関連(Health Care)
概要 事業概要 デクスコム(DexCom Inc.)は医療機器のメーカーである。同社は糖尿病患者および医療提供者が使用する継続的グルコースモニタリング(CGM)システムの設計、開発、および商品化に注力する。同社の製品はDexCom G4 PLATINUMとDexCom G5 Mobileで構成される。同社は第5世代CGMシステムを商業化する。同社の欧州連合(EU)、オーストラリア、ニュージーランド、アジアおよび中南米諸国、米国の米国食品医薬品局(FDA)の承認を得る同社の市場であるDexCom G4 PLATINUMをコンソーシアム・ユーロピーン・マーキング(CEマーク)のもとにある。共有リモート監視システムを備えたDexCom G4 PLATINUMは、患者の受信機と患者のiPhone、iPod touch、またはiPad上のアプリケーションとの間のワイヤレス接続を使用して、指定された受信者(フォロワー)のモバイルデバイス上のアプリケーションにグルコース情報を送信する。   デックスコムは米国の医療デバイスメ―カ―。糖尿病患者および病院用に血糖値測定器の設計、開発、商品化に従事。製品には通院患者用の「SEVEN PLUS」、「DexCom G4」、「DexCom G4 PLATINUM」、および病院用の「GlucoCLear」などがある。  DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) products. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of patients, caregivers, and clinicians, Dexcom simplifies and improves diabetes management around the world.
本社所在地 6340 Sequence Drive San Diego CA 92121 USA
代表者氏名 Kevin R. Sayer ケビン・R・セイヤー
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 858-200-0200
設立年月日 36281
市場名 NASDAQ National Market System
ipoyear 2005年
従業員数 2990人
url www.dexcom.com
nasdaq_url https://www.nasdaq.com/symbol/dxcm
adr_tso
EBITDA EBITDA(百万ドル) -2.90000
終値(lastsale) 123.395
時価総額(marketcap) 10902655673.535
時価総額 時価総額(百万ドル) 10823.58
売上高 売上高(百万ドル) 832.50000
企業価値(EV) 企業価値(EV)(百万ドル) 10559.78
当期純利益 当期純利益(百万ドル) 100.30000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 DexCom Inc. revenues increased 36% to $426.9M. Net income totaled $6M vs. loss of $38.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Interest income increase from $700K to $3.7M (income) Research and development decrease of 1% to $92M (expense).

 DXCMのテクニカル分析


 DXCMのニュース

   Blood Glucose Meters Global Market Report 2021 Featuring Abbott, Roche, Medtronics, Ascensia and Dexcom - ResearchAndMarkets.com  2021/09/01 12:51:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Blood Glucose Meters Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com''s offering. The global blood glucose meters market is expected to grow from $2.92 billion in 2020 to $3.99 billion in 2021 at a compound annual growth rate (CAGR) of 36.6%. The market is expected to reach $4.96 billion in 2025 at a CAGR of 5.6%. Major players in the blood glucose meters market are Abbott, Roche, Medtronics, Ascensia
   Digital Diabetes Management Market to Observe Strong Expansion by 2027 | Key Players - Becton Dickinson and Company, Dexcom, Inc, F. Hoffmann-La Roche Ltd., Johnson and Johnson, Medtronic Plc., Novo Nordisk A/S, Terumo corporation  2021/09/01 11:11:20 OpenPR
"Global Digital Diabetes Management Market Analysis to 2027" is a detailed and comprehensive report on the market, with a special focus on global market trends. market report provides the market overview, including detailed segmentation and sub-segments. It is expected that
   Worldwide Remote Patient Monitoring Industry to 2026 - Featuring Abbott Laboratories, Dexcom and Medtronic Among Others - ResearchAndMarkets.com  2021/09/01 10:23:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Remote Patient Monitoring Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com''s offering. The global remote patient monitoring market reached a value of US$ 964 Million in 2020. Looking forward, the publisher expects the global remote patient monitoring market to exhibit strong growth during the next five years. Companies Mentioned Abbott Laboratories AMD Global Telemedicine Inc. B
   Digital Diabetes Device Market Size 2021 by Product Sales, Revenue, Price, Market Share, Growth Opportunity and Forecast to 2027 Research Report I Top key players-Lifescan, Roche, Medtronic, Ascensia Diabetes Care, TANDEM Diabetes Care, DEXCOM, Social D  2021/08/30 11:15:37 OpenPR
Digital diabetes devices are the executives'' arrangements are cell phone associated diabetes the board gadgets and programming stages utilized by patients experiencing Type 1, Type 2, and gestational diabetes. Clinical experts likewise utilize these answers to oversee diabetes. Get sample copy
   The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration  2021/08/27 11:35:25 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN ) Alkermes plc (NASDAQ: ALKS ) BeyondSpring Inc. (NASDAQ: BYSI ) ( moved on a co-development and commercialization agreement for chemotherapy-induced neutropenia treatment candidate) BioLife Solutions, Inc. (NASDAQ: BLFS ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN ) DexCom, Inc. (NASDAQ: DXCM ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Erasca, Inc. (NASDAQ: ERAS ) Fulcrum Therapeutics, Inc. (NASDAQ: FULC ) Imago BioSciences, Inc. (NASDAQ: IMGO ) MiMedx Group, Inc. (NASDAQ: MDXG ) Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE ) Nuvalent, Inc. (NASDAQ: NUVL ) (IPOed July 29) PDS Biotechnology Corporation (NASDAQ: PDSB ) Prothena Corporation plc (NASDAQ: PRTA ) Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) Repligen Corporation (NASDAQ: RGEN ) ShockWave Medical, Inc. (NASDAQ: SWAV ) Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 26) Alzamend Neuro, Inc. (NASDAQ: ALZN ) Edgewise Therapeutics, Inc. (NASDAQ: EWTX ) FibroGen, Inc. (NASDAQ: FGEN ) MaxCyte, Inc. (NASDAQ: MXCT ) Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM ) Theravance Biopharma, Inc. (NASDAQ: TBPH ) TScan Therapeutics, Inc. (NASDAQ: TCRX ) Stocks In Focus Immutep Announces Award of Chinese Patent For Out-licensed Antibody Treatment Candidate For Cancer and Infectious Disease Immutep Limited (NASDAQ: IMMP ) announced the grant of a patent entitled "Antibody molecules to LAG-3 and uses thereof"
   Grandview Asset Management LLC Buys Vanguard High Dividend Yield Indx ETF, Berkshire Hathaway ...  2021/07/21 20:38:19 GuruFocus
Related Stocks: VYM , BRK.B , PPL , SPY , PFF , DUK , BIBL , VZ , TWTR , WM , VO , DXCM , VB ,
   Marathon Asset Management Llp Buys Booking Holdings Inc, Berkshire Hathaway Inc, TJX Inc, Sells ...  2021/07/21 18:38:17 GuruFocus
Related Stocks: BKNG , BRK.B , TJX , GOOG , TXN , KMB , MMC , DXCM , PYPL , AMAT , KO , BAX , USB , COST ,
   Implantable Sensor Market is expected to reach US$ 11,415.62 Mn by Analog Devices, Inc.; DEXCOM, INC.; Glusense Ltd.; Honeywell International Inc.; Medtronic; NXP SEMICONDUCTORS N.V.; Pinnacle Technology Inc.; Sensirion AG; TE Connectivity; and Texas Inst  2021/07/21 13:09:14 OpenPR
According to our latest study on Implantable Sensor Market Forecast to 2027 COVID-19 Impact and Global Analysis by Type, Application and End User, the market was valued at US$ 4,912.00 million in 2019 and it is projected to
   Eagle Health Investments LP Buys American Well Corp, DexCom Inc, Outset Medical Inc, Sells ...  2021/07/19 20:38:11 GuruFocus
Related Stocks: DXCM , OM , INSP , MRTX , ARGX , AXNX , AMWL , KYMR , CCCC , ARVN , OLK , TMO , JWS , DFHT ,
   Dexcom Inc Shares Approach 52-Week High - Market Mover  2021/07/17 16:04:35 Kwhen Finance
Dexcom Inc (DXCM) shares closed today at 1.7% below its 52 week high of $456.23, giving the company a market cap of $43B. The stock is currently up 21.4% year-to-date, up 8.6% over the past 12 months, and up 478.6% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.0%. Trading Activity Trading volume this week was 32.4% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.4. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 311.1% The company's stock price performance over the past 12 months lags the peer average by -37.7% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 1298.2% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Wearable Healthcare Devices Market: 2021 Global Analysis by Type, Application (Fitness, RPM), Product, Grade, Channel and Top Companies - Biotelemetry Inc.(US), Apple, Inc. (US), Dexcom Inc. (US), Abbott Laboratories(US), Masimo Corporation(US)  2021/06/25 07:16:08 OpenPR
This Wearable Healthcare Devices Market report works as an established source of information to offer a telescopic view of the current market trends, situations, opportunities, and status. The report is divided into several characters which include manufacturers, region, type, application,
   DexCom, Nick Jonas and Leading Diabetes Nonprofits Launch Initiative to Help Improve the Lives of People With Diabetes  2021/06/24 14:00:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)---- $DXCM #DXCM--DexCom, Nick Jonas and Leading Diabetes Nonprofits Launch Initiative to Help Improve the Lives of People With Diabetes
   Diabetes Care Devices Market Growth and Major key players operating in the market are Abbott Laboratories, Dexcom, Johnson & Johnson Services, Merck, Roche, Becton-Dickinson and Company, Novo Nordisk A/S, Bayer AG, Medtronic, Terumo Corporation, Ascensia  2021/06/21 12:45:35 OpenPR
Precision Business Insights published a research report on "Global Diabetes Care Devices Market by Product Type (Blood glucose monitoring devices (Self-monitoring Blood Glucose Meters, Continuous Glucose Meters, Consumables, Others), Insulin delivery devices (Insulin Syringes, Insulin Pens, Insulin Pumps, Insulin Jet
   Insights on the Smart Medical Devices Global Market to 2027 - Featuring Abbott Laboratories, Apple and Dexcom Among Others - ResearchAndMarkets.com  2021/06/21 09:20:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Smart Medical Devices - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com''s offering. Amid the COVID-19 crisis, the global market for Smart Medical Devices estimated at US$8.2 Billion in the year 2020, is projected to reach a revised size of US$30.7 Billion by 2027, growing at a CAGR of 20.8% over the period 2020-2027. Diagnostics & Monitoring Devices, one of the segments analyzed in the report, is projected to record 19.
   Digital Health Service Market Will Hit Big Revenues In Future | Cityzen Sciences, Companion Medical, DexCom  2021/06/19 07:00:00 iCrowdNewswire
The Latest Released Digital Health Service market study has evaluated the future growth potential of Global Digital Health Service market and provides information and useful stats on market structure and size. The []

 関連キーワード  (医療機器_医療用品_ディストリビュ―タ― 米国株 デックスコム DXCM DexCom Inc.)

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)